Xgeva is a bone targeting medicine preventing the breakdown of bone. It inhibits the function of cells that break down bone (osteoclasts) and inhibit bone resorption. They differ because Xgeva has a stronger effect than a bisphosphonate. Xgeva can also strengthen the bone and decrease the number of metastatic cancers that spread to the bone and decrease the risk of a pathological fracture.